Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 4, 1998, Pages 391-401

  Herrlin, Karin ^b   Massele, Amos Y ^b   Jande, Mary ^b   Alm, Christina ^b   Tybring, Gunnel ^b   Abdi, Yakoub Aden ^b   Wennerholm, Agneta ^b   Johansson, Inger ^b   Dahl, Marja Liisa ^b   Bertilsson, Leif ^b   Gustafsson, Lars L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CYTOCHROME P450; DEBRISOQUINE; MEPHENYTOIN; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADOLESCENT; ADULT; ALLELE; ARTICLE; ASIAN; DRUG METABOLISM; EPILEPSY; ETHNIC GROUP; FEMALE; GASTRITIS; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TANZANIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; ANTI-ULCER AGENTS; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; ENZYME INHIBITORS; FEMALE; GENOTYPE; HUMANS; MALE; MEPHENYTOIN; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MUTATION; OMEPRAZOLE; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; REFERENCE VALUES; TANZANIA;

EID: 13144258722     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90070-4     Document Type: Article

References (46)

1. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 1995;29: 192-209.
2. Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990;12: 415-6.
3. Ward SA, Helsby NA, Skjelbo E, Brøsen K, Gram LF, Breckenridge AM. The activation of the biguanide anti-malarial proguanil cosegregrates with the mephenytoin oxidation polymorphism: a panel study. Br J Clin Pharmacol 1991;31:689-92.
4. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villén T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 1989;45:348-55.
5. Skjelbo E, Brøsen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991;49:18-23.
6. Sindrup, Brøsen K. Pharmacokinetics of citalopram in relation to the sparteine and mephenytoin oxidation polymorphism. Ther Drug Monit 1993;15:11-7.
7. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press; 1992. p. 657-85.
8. Kalow W, Bertilsson L. Interethnic factors affecting drug response. Adv Drug Res 1995;25:1-53.
9. Inaba T, Jurima M, Kalow W. Family studies of mephenytoin hydroxylation deficiency. Am J Hum Genet 1986; 38:768-72.
10. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
11. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin hydroxylase in Japanse. Mol Pharmacol 1994;48: 594-8.
12. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L. CYP2C19 genotype and phenotype determined by omeprazole in a Korean Population. Pharmacogenetics 1996;6:547-51.
13. Wedlund PJ, Aslanian WS, McAllister CB. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984;36:773-80.
14. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995;57:662-9.
15. Chang M, Tybring G, Dahl ML, Götharson E, Sagar M, Seensalu R, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole: suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995;39:511-8.
16. Chang M, Dahl ML, Tybring G, Götharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995;5:358-63.
17. Cavalli-Sforza LL, Menozzi P, Piazza A. The history and geography of human genes. 1st ed. Princetown: Princetown University Press; 1994. p. 168.
18. Watkins WM, Mberu EK, Nevill CG, Ward SA. Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans R Soc Trop Med Hyg 1990;84:492-5.
19. Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg M. S-Mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 1996;6:521-6.
20. Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995;57:656-61.
21. Sanz E, Villén T, Alm C, Bertilsson L. S-Mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989;45:495-9.
22. Zhang Y, Blonin RA, McNamara P, Steinmetz J, Wedlund PJ. Limitation to the use of the urinary S/R-mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 1991;31:350-2.
23. Wedlund PJ, Sweetman BJ, McAllister CB, Branch RA. Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Chromatogr 1984;307:121-7.
24. Tybring G, Bertilsson L. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics 1992;2:241-3.
25. Lagerström PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 1984;309:347-56.
26. Tybring G, Böttiger Y, Widén J, Bertilsson L. Enantio-selective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish healthy subjects. Clin Pharmacol Ther 1997;62:129-37.
27. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996;278:441-6.
28. Edeki TI, Goldstein JA, de Morais SMF, Hajiloo L, Butler M, Chapdelaine P, et al. Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans. Pharmacogenetics 1996;6:357-60.
29. Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992;2:25-31.
30. Ishizaki T, Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Asians. Ther Drug Monit 1994;16:214-5.
31. Iyun AO, Tucker GT, Wooks HF, Lennard MS. The 4-hydroxylation of (S)-mephenytoin in Nigerians: a population study. Ingelman-Sundberg M, Gustafsson JA, Orrenius S, editors. Eighth International Symposium of Microsomes and Drug Oxidation, Stockholm, June 25-29, 1990.
32. Masimirembwa CM, Gustafsson LL, Dahl ML, Abdi YA, Hasler JA. Lack of effect of chloroquine on debrisoquine (CYP2D6) and S-mephenytoin (CYP2C9) hydroxylation phenotypes. Br J Clin Pharmacol 1996;41:344-6.
33. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7.
34. Andersson T, Miners JO, Veronese M, Tassaneeyakul W, Meyer UA, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993;36:521-31.
35. Rost KL, Brockmöller J, Esdorn F, Roots I. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. J Hepatol 1995;23:268-77.
36. FAO Food balance sheets 1992-94 average. Rome: Food and Agricultural Organization of the United Nations; 1996.
37. O'Neil WM, Di Girolamo A, Gilfix BM, Flockhart DA, Tsoukas CM, Wainer IW. The genotype and expressed phenotype of cytochrome P450 2D6 among HIV+/AIDS patients [abstract]. Clin Pharmacol Ther 1998;63:151.
38. Skjelbo E, Mutabingwa TK, Bygbjerg, Nielsen KK, Gram LF, Brøsen K. Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther 1996;59:304-10.
39. Conney AH. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G.H.A. Clowes memorial lecture. Cancer Res 1982;42:4875-917.
40. Guengerich FP, Shimada T, Yun CH, Yamazaki H, Raney KD, Thier R, et al. Interactions of ingested food, beverage, and tobacco components involving human cytochrome P4501A2, 2A6, 2E1 and 3A4 enzymes. Environ Health Perspect 1994;9:49-53.
41. Gauthier I, Malone M. Drug-food interactions in hospitalised patients. Drug saf 1998;18:383-93.
42. Campbell TC. Nutrition and drug-metabolizing enzymes. Clin Pharmacol Ther 1977;22:699-706.
43. Ueng YG, Kuwabara, Chun, Guengerich FP. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 1997;36:370-81.
44. Gallagher EP Kunze KL, Stapleton PL, Eaton DL. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4. Toxicol Appl Pharmacol 1996;141: 595-606.
45. Schrenk D, Brockmeier D, Mörike K, Bock KW, Eichelbaum M. A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur J Clin Pharmacol 1998;53:361-7.
46. Aden Abdi Y, Gustafsson LL, Ericsson Ö, Hellgren U. Drug treatment of tropical parasitic infections. 2nd ed. London: Taylor and Francis; 1995.